USE OF MACHANOCHEMICALLY ACTIVATED CHARGED NANOPARTICLES OF DOXORUBICIN AS A FACTOR LIMITING COMPLICATIONS IN POLYCHEMOTHERAPY OF PATIENTS WITH MALIGNANT LYMPHOMAS
S.A. Sivkovich, V.E Orel, N.N. Dzyatkovskaya
Objective of a study — analysis of clinical use of machanochemically activated (MA) charged nanoparticles of doxorubicin (DR) as a factor lim iting complications in polychemotherapy (PCT) of patients with malignant lymphomas. A study was performed in 17 patients with nonHodgkin’s lym phomas (NHL), 23 patients with Hodgkin’s lym phomas (HL) and 60 noninbred rats with Pliss’ lymphosarcoma. Mechanochemical activation of charged nanoparticles DR was performed with in tensity of power supply of 20 W/g. Antitumor ef fect of MA DR on the animals with Pliss’ lympho sarcoma was 1,5fold more effective than the effect of officinal DR. During PCT of HL and NHL pa tients using of MA DR decreased complications dur ing and some days after sessions of chemotherapy by 41% as well as increased frequency of complete remission by 35%. Use of MA DR in schedules of PCT increased 5year survival of NHL patients by 9% and HL patients by 24%. Use of MA nanopar ticles DR in the schedules of PCT of HL and NHL patients limits complications and increases 5year survival of patients.
No comments » Add comment